anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Skin aging is a complex biological process that can be categorized into either extrinsic or intrinsic aging. Intrinsic aging is an inherent degenerative process caused by decreased proliferative capacity leading to cellular senescence. Extrinsic aging is caused by factors such as UV radiations, smoking and alcohol consumption.The physiological changes associated with aging of the skin are manifested in xerosis, dramatic loss of skin elasticity due to damage to collagen and elastin fibers; as well as barrier function, modification of rhytides and deficiencies in the regenerative property of the skin. All of which ultimately result in thinning of the skin, malar fat atrophy and pigmentary changes.Aging skin undergoes thinning of the epidermis that is caused by reduction of vascularity and hydration. On average, the thickness of the epidermis is reduced by about 6.4% during each decade of life.Skin aging effects can be assessed based on the skin appearance (texture and roughness, fine lines and wrinkles), structure, elasticity, hydration and barrier function. Many new non-invasive or minimally invasive bioengineering advances in recent years have enabled the quantitative analysis of skin properties during the aging processRecently, adult stem cells such as mesenchymal stem cells (MSCs) have been used in variable dermatologic conditions due to its regenerative properties such as wound healing, rejuvenation, acne scar and hair fall treatment. Different types of MSCs could be derived from different tissues as for example; bone marrow stem cells (BMSCs), adipose tissue-derived stem cells (ADSCs), and skin-derived stem cells (SDSCs)Adipose tissue derived stem cells are currently favorable compared to other types of adult stem cells as the procedure is easy, safe with minimal donor site morbidity. The process of obtaining a considerable amount of adipose tissues sufficient to use in skin regeneration is highly appealing due to its relative availability and accessibility. They secrete variable growth factors that affect surrounding environment as vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), insulin like growth factors (IGF) and others
The invention relates to a metronidazole-furazolidone vaginal expandable suppository and its preparation method and detection method. The metronidazole-furazolidone vaginal expandable suppository comprises a drug-containing matrix comprising active components and a matrix, and also comprises an expandable carrier. The active components comprise metronidazole and furazolidone. The active components further comprise alum, borneol and frankincense. A clathrate is prepared from metronidazole and hydroxypropyl-beta-cyclodextrin. A solid dispersion is prepared from furazolidone, alum, frankincense, borneol and a sustained-release material. The metronidazole-furazolidone vaginal expandable suppository comprises a quick release part and a slow release part and has effects of fast and stably inhibiting bacteria. The metronidazole-furazolidone vaginal expandable suppository is a hollow two-layer expandable suppository and thus suppository stability is improved. The metronidazole-furazolidone vaginal expandable suppository adopts seven unique technologies and has the advantages of drug liquid flowing-out prevention, high stability, long action time and secondary infection prevention.
A template may be formed from such as surgical tape, having an opening cut therein in the shape of an eyebrow. The template may have a low-tack adhesive coating on one side, or a depilatory coating, or one of each on both sides of the substrate. When used for eyebrow shaping, the adhesive side is adhered to the skin, and colouring is applied through the opening. When used for waxing, the depilatory coating is applied to the region around the shape of the eyebrow to be left after the depilation procedure. The depilatory coating may be a heat-activated composition, or a pressure-activated composition. The templates may be provided in pairs, in rolls of groups of pairs.
PROBLEM TO BE SOLVED: To obtain an alcohol-decomposing composition having strong alcohol- decomposing action, decomposing alcohol inside the stomach and preventing excess alcohol absorption by freeze-drying an acetic acid bacterium decomposing alcohol below a specific acidic pH and mixing the dried microbes therein. SOLUTION: An acetic acid bacterium decomposing alcohol below pH3 (e.g.; Acetobacter aceti IFO 3281, etc.) is cultured and separated to the culture medium and the bacterial cells by centrifugation, to collect the cells. The cells are freeze- dried and made to powder, and the powdery material is formulated to a powder agent, a tablet, a capsule agent, a granule, a liquid agent or a drink, etc., by adding additives such as an extending agent, an excipient, etc., according to shapes of the formulation products to obtain the objective alcohol-decomposing composition. The composition has a strong alcohol-decomposing action and when taken in drinking of alcohol or before the drinking, alcohol is oxidized to acetic acid through acetaldehyde by the acetic acid bacterium inside the stomach, thus excess alcohol absorption is prevented.
A main aim of the project is to investigate how the effects of an ABM intervention on depressive symptoms are mediated by transdiagnostic rumination and how characteristics of the symptom network moderate these effects. The Affective Bias Modification Task (ABM) will be applied in a randomized controlled, double blind clinical trial with 6 months follow-up. Personalized networks are generated from prospective assessment of depression-related processes at baseline and follow-ups. Patients (n = 150) will be recruited from out-patient clinics at Diakonhjemmet Hospital, and randomized into one of three conditions: active, sham and assessment only. Patients aged 18-65 with depression (major depressive disorder) or bipolar disorder 2, with or without comorbid anxiety and/or alcohol use disorder will be included. The main hypothesis is that subjects who are in the active ABM group will exhibit less tendency for stress related (state) rumination compared to those in the placebo group. Active vs placebo ABM will decrease depressive symptoms (6 months) and this effect will be mediated by the change in state rumination. Densely connected symptom network and high strength centrality of rumination at baseline will moderate the effect of ABM. By combining mechanisms research with a personalized symptom network approach, this study will be in the forefront of understanding how a drug-free treatment option works and for whom it works best.
Cardiac mapping catheters and methods for using the catheters are described. The catheter can detect the presence, direction and/or source of a depolarization wave front associated with cardiac arrhythmia. A mapping catheter includes a plurality of bipolar electrode pairs in which the members of each pair are opposed to one another across a perimeter, for instance in a circular pattern (compass mode). The spaced arrangement of the electrodes can be utilized to identify directional paths of moving electric fields or wave fronts in any direction passing across the endocardial surface. Double potential (DP) recordings in compass mode can provide a regional assessment for the existence of rotational activity. Simultaneous DP recordings in compass mode, narrow-adjacent bipolar, and unipolar recording provide an accurate assessment of the time, location, and path that a rotational mechanism breaches a perimeter of electrodes. Accurate time, location, and path of perimeter breaches can be used to electrically track rotational mechanisms during atrial fibrillation.
The invention provides a lucid ganoderma composition for assisting in inhibiting tumors and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The ganoderma lucidum composition mainly comprises the following raw materials in parts by weight: 8-12 parts of ganoderma lucidum spore oil, 7-8 parts of emblic leafflower fruit, 2-4 parts of giant knotweed, 2-3 parts of Indian iphigenia bulb and 3-5 parts of malaytea scurfpea fruit. The Ganoderma composition contains Ganoderma spore oil as main material, and adjuvant drugs for inhibiting tumor hyperplasia, improving body condition of people, and nourishing body. The emblic leafflower fruit, the giant knotweed rhizome, the Indian iphigenia bulb and the malaytea scurfpea fruit are used as auxiliary raw materials, so that the effect of assisting in inhibiting tumor division and proliferation is further achieved, and the effect of the lucid ganoderma composition is improved. In addition, the ganoderma lucidum composition has good effect of protecting heart and cerebral vessels and liver, and is suitable for people suffering from heart and cerebral vascular diseases or liver diseases. In addition, the preparation method of the ganoderma lucidum composition extracts the effective components in the raw materials in a simple and convenient manner, and the curative effect is better.
The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hydrogel that includes the amphiphilic linear peptide/peptoid. The amphiphilic linear peptide/peptoid is capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water, and forming a hydrogel. These peptides/peptoids include short amphiphilic sequences with a hydrophobic portion of aliphatic amino acids and at least one acidic, neutral, or basic polar amino acid. The amphiphilic linear peptide/peptoid is build up of non repetitive aliphatic amino acids, which may be in the L- or D-form. A plurality of such peptides/peptoids assembles to supramolecular helical fibers and forms peptide hydrogels after assembly. A corresponding hydrogel is formed in aqueous solutions at physiological pH and is thus useful for inter alia cell culture, tissue engineering, tissue regeneration, wound healing and release of bioactive moieties (including cells, nucleic acids, anti-microbials, micro-/nanoparticles, cosmetic agents and small molecule therapeutics), as well as for providing mechanical support for damaged or missing tissues. Such hydrogels can also be formed in situ, wherein the gelation process occurs within the body following the injection of a peptide solution. Such hydrogels, which are rigid, biocompatible and entrap up to 99.9% of water, are also well suited for applications utilizing electronic devices.
This experiment was carried out to investigate the nutritional value of Spirulina and Dunaliella (SD) combination levels (0, 0.5, 1.0, 1.5, and 2.0 g/kg) that affected the laying Japanese quail's efficiency, egg quality, fertility, and blood biological indicators. A total of 150 adult Japanese quails, aged 8 wk, were divided into 5 treatments at random, each consisting of 30 quails. There were 5 duplicates for every treatment, with 2 male and 4 female quails in each. Comparing the addition of various concentrations of a mixture of SD to the control treatment, the results showed no substantial rise in egg production, egg weight, or egg mass. When compared to the control group, final body weight (FBW) was improved with SD supplementation. The quails in control consumed more feed intake (FI) (p < 0.05), and they were different from the groups who got SD therapy in that they had a regular feed conversion ratio (FCR). The percentages of hatchability and fertility increased when SD was added to quail meals at up to 1.00 g/kg. When compared to the control quail, the quail supplemented with SD levels showed a non-significant rise in albumin%, yolk%, Haugh unit, and unit surface shell weight (USSW), as well as an increase in eggshell percentage and a drop in egg shape index (p < 0.05). Renal and hepatic enzyme functioning improved when SD was added to the diets. Additionally, lipid profile indicators were reduced by SD supplementation (except low-density lipoprotein-LDL). Moreover, compared to the control, incorporating SD led to a nonsignificant rise in immunoglobulin concentrations (IgG and IgM). In conclusion, adding SD to the diet can improve body weight, lipid profile, immunological response, and liver and kidney functions in Japanese quail.
Chronic use of cholestyramine resin may be associated with increased bleeding tendency due to hypoprothrombinemia associated with Vitamin K deficiency. This will usually respond promptly to parenteral Vitamin K1 and recurrences can be prevented by oral administration of Vitamin K1. Reduction of serum or red cell folate has been reported over long term administration of cholestyramine resin. Supplementation with folic acid should be considered in these cases.

There is a possibility that prolonged use of cholestyramine resin, since it is a chloride form of anion exchange resin, may produce hyperchloremic acidosis. This would especially be true in younger and smaller patients where the relative dosage may be higher. Caution should also be exercised in patients with renal insufficiency or volume depletion and in patients receiving concomitant spironolactone. Cholestyramine resin may produce or worsen preexisting constipation. The dosage should be increased gradually in patients to minimize the risk of developing fecal impaction. In patients with pre-existing constipation, the starting dose should be 1 pouch or 1 scoop once daily for 5 to 7 days, increasing to twice daily with monitoring of constipation and of serum lipoproteins, at least twice, 4 to 6 weeks apart. Increased fluid intake and fiber intake should be encouraged to alleviate constipation and a stool softener may occasionally be indicated. If the initial dose is well tolerated, the dose may be increased as needed by one dose/day (at monthly intervals) with periodic monitoring of serum lipoproteins. If constipation worsens or the desired therapeutic response is not achieved at one to six doses/day, combination therapy or alternate therapy should be considered. Particular effort should be made to avoid constipation in patients with symptomatic coronary artery disease. Constipation associated with cholestyramine resin may aggravate hemorrhoids.
Enterprise organizations may use observational data to gather information about user experiences with their products and tools. For instance, patients with kidney failure may undergo dialysis treatment in order to remove toxins and excess fluids from their blood. The dialysis treatment may be performed at a hospital or clinic, or in a user's home, and the enterprise organization may use gathered information to gain understanding of user experiences with their dialysis machines and services. A user experience computing system gathers and processes user experience information from across the enterprise organization. Using stored observation data (e.g., surveys, studies etc.) in its smallest common form, the computing system may use this data as building blocks for creating more complex data objects (e.g. journey matrices and/or empathy gardens) using inputs from multiple different sources, and to facilitate presenting this information in an effective and empathetic way to product developers.
Healthy subjects aged 0-18 years old. Subjects cannot have a presence or past history of a neurological disorder or other disease that would be expected to substantially impact health.
All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
KETALAR is a clear, colorless sterile solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if product is discolored or contains particulate matter.

Induction of Anesthesia: Do not intravenously inject the 100 mg/mL concentration of KETALAR without proper dilution. Dilute KETALAR with an equal volume of either Sterile Water for injection, USP, 0.9% Sodium Chloride Injection, USP (Normal Saline), or 5% Dextrose in Water. Use immediately after dilution.

Maintenance of Anesthesia: To prepare a dilute solution containing 1 mg of ketamine per mL, aseptically transfer 10 mL from a 50 mg per mL vial or 5 mL from a 100 mg per mL vial to 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (Normal Saline) and mix well. The resultant solution will contain 1 mg of ketamine per mL. Use immediately after dilution.

When fluid restriction is required, KETALAR can be added to a 250 mL infusion as described above to provide a KETALAR concentration of 2 mg/mL. 

KETALAR 10 mg/mL vials are not recommended for dilution.
FIELD: medicine. SUBSTANCE: method involves carrying out two-stage course of curative nutrition in combination with cleansing enema and Glauber's salt intake. The first stage: intake of freshly prepared apple juice and heater applying on liver zone, intake of olive oil and lemon juice. During the first stage (5 days) boiled vegetables were used as foodstuffs. The second stage: intake a mixture of snow melt water and freshly prepared grapefruit, orange and lemon juices for 4 days and the forth day is terminated by heater applying on liver zone and intake of olive oil and lemon juice. During both stages infusion prepared of the following plant raw is intaken every day before night: Benx rose petals, lotus leaves, sesame seeds and Naples palm leaves taken at equal amount. For cleansing enema decoction of the following medicinal herbs is used: matricary flowers, milfoil, horse-tail, tansy inflorescence, common immortelle flowers at ratio of components = 1: 1:1:1:1. After carrying out the curative nutrition stages a mixture of black radish and beet juices with vodka and honey is intaken. Method can be used for treatment of different pathology, disorders and prophylaxis. EFFECT: enhanced effectiveness of method. 1 tbl
In the absence of successful regeneration treatments to recover normal neurological function after spinal cord injury, there has been a needed focus on research aimed at preventing or minimizing the secondary complications of living with a spinal cord injury (SCI). Approximately 44,000 persons live with traumatic spinal cord injury in Canada, half of which have tetraplegia, with 35 new spinal cord injuries (SCI) per million each year. Persons with spinal cord injury SCI are among the most sedentary on the planet, with a much higher incidence of related diseases, such as obesity, glucose intolerance, diabetes and cardiovascular disease than the able-bodied population. At the same time, information needed to minimize the risk of developing these diseases for those living with spinal cord injury is lacking. For example, specific information regarding resting energy requirements, energy expenditure during exercise, and the volume of exercise required to maintain a healthy body composition and prevent the development of sedentary-related disease in this population is scarce.

In order to maintain weight, and not gain excess body fat, energy intake in food Calories needs to match energy use. In addition to understanding energy use in order to maintain weight balance, exercise is also important for muscular and cardiovascular health. Research to date indicates that the resting energy expenditure of persons with SCI is considerably less than able-bodied persons with the same weight or body mass index. A considerable portion of this reduced resting energy expense is due to the reduced muscle mass after SCI. There are mixed research results regarding whether there are additional reductions in resting energy expenditure, after adjusting for fat free mass, in persons with SCI. Training has been shown to be effective in reducing shoulder pain, improving function, improving physical capacity, reducing hyperinsulinemia, and reducing dyslipidemia in persons with chronic paraplegia.

However, it is less clear if voluntary exercise can have the same beneficial effects for those living with tetraplegia, in part because their peak power output is only one-third to one-half that achieved during arm exercise in those with paraplegia. In addition, it may be very difficult for those with tetraplegia to be able to exercise for a sufficient duration to achieve a sufficient training effect to either maintain a healthy body composition or reduce the risk of developing the sedentary diseases common to this population. This study will provide the exercise-related energy expenditure data to address this question.
PURPOSE:To obtain tea solution containing gamma-aminobutyric acid, but not tannin thus having preventive effect on hypertensive diseases, by adding insoluble polyvinylpyrrolidone to the extract from anaerobically treated tea leaves and filtering. CONSTITUTION:Anaerobically treated tea leaves are extracted with warm water and the extract is filtered. The filtrate is combined with about 5-30wt.%, based on the tea leaves, of insoluble polyvinyl pyrrolidone, then the mixture is filtered to give the subject tea solution. The tannin-removed solution or a concentrate thereof is combined with at least cyclodextrin or more preferably at least the tea extract or the tea extract and cyclodextrin are added to give the tea beverage using tannin-free tea extract. This treatment removes the strange smell characteristic in anaerobically treated tea to give a tea drink having refreshing taste. The tea beverage represses the increase of blood pressure in relatively hypertensive aged people.
BACKGROUND: Heart failure is associated with reduced quality of life, hospitalizations, death and high healthcare costs. Despite care improvements, the rehospitalization rate after an acute heart failure episode, especially for acute heart failure, remains high.
METHODS: The Education Strategy for patients with acute Heart Failure (EduStra-HF; ClinicalTrials.gov Identifier NCT03035123) study will randomize patients admitted for acute heart failure in six French hospitals to usual care (control) or therapeutic education (intervention). All patients will be evaluated at baseline and will meet with a therapeutic education nurse before discharge. Those in the usual care arm will have standard appointments with their cardiologist and general practitioner. Those in the intervention arm will have an intensive follow-up schedule of phone calls, home visits and text messages from the therapeutic education nurses, plus cardiologist visits. Patients will be stratified by discharge location (home or cardiac rehabilitation centre) before randomization, and will be followed up for 1 year. The primary outcome will be the readmission rates for acute heart failure during 1 year in the two groups. Secondary outcomes will include: quality of life; time from inclusion to first readmission for acute heart failure; non-heart failure cardiovascular rehospitalization rates; length of stay for heart failure; cardiovascular and all-cause death; rates of patients receiving optimal medical therapies; evolution of knowledge about heart failure; and cost-effectiveness.
CONCLUSIONS: This study will assess the efficacy and feasibility of a standardized management strategy for the care and follow-up of patients discharged after hospitalization for acute heart failure. The EduStra-HF strategy will combine various nurse care methods to help prevent rehospitalization.